- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07572981
Study of the Effectiveness of Clinical Hypnosis and Self-hypnosis in Relieving Hot Flashes in Menopausal Women (HYPNOMENO-2)
Study of the Effectiveness of Clinical Hypnosis and Self-hypnosis in Relieving Hot Flashes in Menopausal Women With no Indication for Menopausal Hormone Therapy
The onset of menopause is accompanied by a significant drop in blood estradiol levels, the main symptom of which is hot flashes. These are present in 80% of menopausal women and are debilitating in 25% of cases.
Although estrogen therapy is the most effective treatment for managing menopausal symptoms, numerous non-hormonal alternatives, both pharmacological and non-pharmacological, have been evaluated for managing menopausal symptoms. Among these, hypnosis has shown promise in several studies.
However, to our knowledge, there are no studies that evaluate the longer-term effectiveness of hypnotherapy on menopausal symptoms (beyond 3 months after the start of treatment). Furthermore, there is very little data on the effectiveness of hypnotherapy on the overall quality of life of these women, independent of hot flashes, nor on other symptoms related to menopause. A first pilot study, neither randomized nor controlled, is currently underway, and we hope to continue the project with a robust controlled study.
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Christelle MOREAU
- Telefonnummer: +33 0567771182
- E-post: moreau.c@chu-toulouse.Fr
Studiesteder
-
-
Oui
-
Toulouse, Oui, Frankrike, 31300
- Centre de ménopause, Hôpital Paule de Viguier, 330 avenue Grande Bretagne
-
Ta kontakt med:
- Emeline MULLER
- Telefonnummer: 0561778707
- E-post: muller.e@chu-toulouse.Fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Adult patient
- Patient with amenorrhea for at least 12 months or with a history of bilateral oophorectomy.
- Patient with debilitating symptoms related to menopause, who consulted a physician at the Menopause and Osteoporosis Prevention Center at Paule de Viguier Hospital, Toulouse University Hospital, and was referred for hypnosis consultation by that physician.
Exclusion Criteria:
- Patient under 18
- Patient undergoing menopausal hormone therapy
- Patient using another therapeutic alternative for hot flashes validated against placebo in the literature at the time of inclusion: neurokinin 3 receptor antagonists, selective serotonin reuptake inhibitors, clonidine, gabapentin, acupuncture
- Patient who had a hypnosis session within the last 6 months
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Standard group without hypnosis
Patient receiving conventional care without hypnosis
|
For the control group: unstructured supportive interview with the nurse
Completion of quality of life questionnaires at inclusion, at 3 months and at 6 months
|
|
Eksperimentell: Experimental group with hypnosis
Patient undergoing hypnosis sessions
|
Completion of quality of life questionnaires at inclusion, at 3 months and at 6 months
For the experimental group: two hypnosis sessions with the nurse
For the experimental group: reinforcement of the hypnosis technique with a group self-hypnosis session
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluation of the effectiveness at 6 months of hypnotherapy on the overall quality of life of menopausal women compared to a simple empathic support technique.
Tidsramme: 6 months after the inclusion
|
The effectiveness of hypnotherapy in treating the side effects of menopause will be assessed with the score calculated from the MENQOL questionnaire at 6 months
|
6 months after the inclusion
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluating the effectiveness of hypnotherapy on women's overall quality of life at 3 months
Tidsramme: 3 months after the inclusion
|
The effectiveness of hypnotherapy in treating the side effects of menopause will be assessed with the score calculated from the MENQOL questionnaire at 3 months
|
3 months after the inclusion
|
|
Evaluate the effectiveness of hypnotherapy on the frequency of hot flashes
Tidsramme: 6 months after the inclusion
|
Measurement of the total number of hot flashes recorded daily over 7 days
|
6 months after the inclusion
|
|
Evaluation of the tolerance of hypnotherapy
Tidsramme: 6 months after the inclusion
|
Measuring tolerance using an adverse event questionnaire
|
6 months after the inclusion
|
|
Evaluation of the effectiveness of hypnotherapy on depressive symptoms
Tidsramme: 6 months after the inclusion
|
Depressive symptoms will be assessed using the validated Patient Health Questionnaire-9 (PHQ-9).
|
6 months after the inclusion
|
|
Evaluation of the effectiveness of hypnotherapy on sleep disorders
Tidsramme: 6 months after the inclusion
|
Sleep disorders will be assessed using the Insomnia Severity Index (ISI) questionnaire.
|
6 months after the inclusion
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- RC31/25/0564
- ID-RCB (Annen identifikator: 2025-A02239-40)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Unstructured supportive interview
-
Norwegian Institute of Public HealthNorwegian University of Science and TechnologyFullførtPsykiske lidelser | Rusmisbruksforstyrrelser | Behandling | DeltakelseNorge
-
Mayo ClinicHar ikke rekruttert ennåSpontan koronararteriedisseksjonForente stater
-
University of ZurichFullførtPosttraumatisk stresslidelse (PTSD) | Kompleks posttraumatisk stresslidelse (CPTSD)Sveits
-
Norwegian Institute of Public HealthStatistics Norway; Society of Interventional OncologyFullførtPsykiske lidelser | Rusmisbruksforstyrrelser | Behandling | DeltakelseNorge
-
Brown UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)FullførtAlkoholavhengighet | AlkoholmisbrukForente stater
-
The National Center on Addiction and Substance...Patient-Centered Outcomes Research Institute; Massachusetts General Hospital og andre samarbeidspartnereRekruttering
-
Mahidol UniversityFullførtScreeningverktøy for depresjon hos kreftsmertepasienterThailand
-
Union de Gestion des Etablissements des Caisses...Clinique Chantecler; Centre Orthopédique Maguelone; Centre Helio Marin; Institut... og andre samarbeidspartnereRekruttering
-
Freeman-Sheldon Research Group, Inc.AvsluttetKraniofaciale abnormiteter | Arthrogryposis | Freeman-Sheldon syndrom | Arthrogryposis Distal Type 2A | Whistling Face Syndrome | Kraniokarpotarsal dysplasi | Kraniokarpotarsal dystrofi | Freeman-Sheldon syndromvariant | Sheldon-Hall syndrom | Arthrogryposis Distal Type 2B | Gordon syndrom | Arthrogryposis Distal... og andre forholdForente stater
-
University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI)Fullført